Evidence map›Paper›PMID 41662148›Full record

ArticleMicrobial biotechnology2026

Development of a Tool for High-Efficiency, Markerless and Iterative Genome Editing in Shouchella clausii.

Claudia Cappella, Carsten Jers, Lorenzo Ninivaggi, Maurizio Bettiga, Ivan Mijakovic, Gennaro Agrimi, Pasquale Scarcia

Abstract read
In one paragraph

Article in Microbial biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Claudia CappellaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, Italy.
Carsten JersNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Lorenzo NinivaggiItalbiotec Srl Società Benefit, Milan, Italy.
Maurizio BettigaItalbiotec Srl Società Benefit, Milan, Italy.
Ivan MijakovicNovo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark.
Gennaro AgrimiDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, Italy.
Pasquale ScarciaDepartment of Biosciences, Biotechnologies and Environment, University of Bari "Aldo Moro", Bari, Italy.ORCID https://orcid.org/0000-0001-6216-0411

Funding

HORIZON EUROPE European Innovation Council 101159570Ministero dello Sviluppo Economico F/310095/01/X56Novo Nordisk Foundation NNF20CC0035580
6 · The paper itself

Abstract

Shouchella clausii is a spore-forming, Gram-positive bacterium with intrinsic antibiotic resistance and promising potential in biotherapeutics, industrial biotechnology and environmental applications. Its genetic intractability, due to a rigid cell wall and lack of natural competence, has limited its development as a microbial chassis. To facilitate its genetic transformation, a hyperosmotic electroporation protocol was optimised using cell wall weakening agents, achieving efficiencies comparable to other recalcitrant bacilli. A comprehensive and reusable genetic tool was developed centred on a temperature-sensitive E. coli-S. clausii shuttle vector (pM4B522) specifically engineered for compatibility with Golden Gate assembly. The plasmid backbone includes a spectinomycin resistance marker and an integrated red fluorescent protein reporter for transformants selection. A removable AmilCP chromoprotein cassette streamlines the assembly process by enabling blue/white screening in E. coli. This plasmid, employing a two-step pop-in/pop-out integration strategy, has demonstrated high versatility for genome editing in both S. clausii and Bacillus subtilis as evidenced by its successful use in multiple cases: (i) sequential, markerless deletions of the non-essential catabolic genes xylA and lacA in S. clausii DSM 8716, with a success rate exceeding 60%; (ii) replacement of the lacA coding sequence with a gfp coding sequence, resulting in fluorescence induction in lactose-supplemented medium; (iii) introduction of a single-base substitution generating a premature stop codon in lacA, showcasing scar-free point mutagenesis; and (iv) transfer of the system to B. subtilis 168, highlighting its broader applicability across Gram-positive bacteria. Given the precision and scarless nature of these genetic modifications, this system holds strong potential for the development of next-generation probiotics and synthetic biology applications.

Indexed as

Gene EditingBacillus subtilisElectroporationEscherichia coliGenetic VectorsPlasmidsTransformation, BacterialBacillus clausiielectroporationgram‐positive bacteriahomologous recombinationmarkerless genome editingShouchella clausiitemperature‐sensitive replication

Identifiers

PMID41662148
PMCPMC12885165

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.